This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.
Listen to a selection of short videos where UK and international experts share their views on the role of ZAVICEFTA® (ceftazidime-avibactam), share their clinical experience through patient cases in cUTI, cIAI or HAP/VAP, and in general about the challenges and management of Gram-negative infections.
Dr Matthew Dryden, Consultant Microbiologist at Hampshire Hospitals, discusses the REPRISE study.
Alex Soriano, Infectious Disease Physician at Hospital Clinic in Barcelona, Spain summarises key ZAVICEFTA data against other β-lactam/β-lactamase inhibitor combinations. He discusses ZAVICEFTA’s in vitro activity and broad-spectrum coverage against MDR P. aeruginosa and Enterobacteriaceae (including Klebsiella pneumoniae, Escherichia coli and ESBL-producing strains).
Clóvis Arns da Cunha, Professor Infectious Disease in Curitiba, Brazil, discusses in vitro activity of ZAVICEFTA (ceftazidime–avibactam) against carbapenemase-resistant Enterobacteriaceae.
Professor Antoni Torres, Professor of Pulmonology and Respiratory Critical Care Medicine at University of Barcelona, Spain, talks about hospital-acquired pneumonia and ventilator-associated pneumonia, as well as the REPROVE study, a Phase III randomised clinical trial comparing ceftazidime-avibactam to meropenem.
Consultant Microbiologist at Hampshire Hospitals, comments on ZAVICEFTA and its role in clinical practice.
Abbreviations
cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; AMR, Antimicrobial Resistance
Prescribing information
Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information
Click here for Meronem® (meropenem trihydrate) Prescribing Information
Click here for Tazocin® (piperacillin sodium, tazobactam sodium) Prescribing Information
Click here for Tygacil® (tigecycline) GB Prescribing Information
Click here for Tygacil® (tigecycline) Northern Ireland Prescribing Information
Click here for Amikacin (amikacin sulfate) Prescribing Information
Click here for Tobramycin (tobramycin) Prescribing Information
Follow the link to learn about out upcoming meetings and online webinars event - dates, location and agendas.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021